Modus Therapeutics Holding AB (DE:99Z)
FRANKFURT:99Z
Want to see DE:99Z full AI Analyst Report?
99Z Stock Chart & Stats
€0.03
>-€0.01(-1.57%)
At close: 4:00 PM EST
€0.03
>-€0.01(-1.57%)
Day’s Range― - ―
52-Week Range€0.01 - €0.33
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€5.04M
Enterprise Value€28.83M
Total Cash (Recent Filing)€5.32M
Total Debt (Recent Filing)€5.00M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
May 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.42
Shares Outstanding121,628,494
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)2.10
Price to Sales (P/S)0.00
P/FCF Ratio-1.05
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Financial LeverageReported zero total debt across 2023–2025 gives Modus structural financial flexibility versus highly leveraged peers. Low leverage reduces near-term default risk and interest burden, preserving scarce cash for R&D and allowing management to prioritize development or strategic partnerships.
Focused Rare‑Disease PipelineA concentrated clinical-stage program targeting sickle cell disease and related rare hematology conditions aligns the company with durable unmet medical need. Focused pipelines can attract specialized investors, partners and regulatory attention, improving odds for accelerated paths and strategic collaborations.
Clinical‑Stage, Lean R&D FocusOperating as a small, clinical-stage R&D entity keeps structural overhead low and concentrates capital deployment on trials and discovery. This lean model can extend runway per spend, make the company an attractive partner for larger pharma, and maintain strategic agility in program prioritization.
Bears Say
Persistent Cash BurnConsistent negative operating and free cash flow, with deterioration in 2025, is a durable constraint on the company’s ability to self‑fund development. Ongoing burn increases dependency on capital markets or partners and raises the probability of dilutive financings or program slowdowns.
Pre‑Revenue With Ongoing LossesA multi‑year pre‑revenue profile and persistent net losses underline a long runway to commercialization. This structural lack of operating income lengthens the timeline to profitability, heightens binary clinical outcome risk for investors, and limits internal funding capacity for growth.
Financing Dependence & Equity VolatilityAlthough debt is low, the balance sheet shows equity volatility and explicit reliance on external funding. Structural dependence on equity raises dilution risk for current holders, can complicate long‑term planning, and may pressure management to prioritize near‑term financing over optimal clinical timelines.
99Z FAQ
What was Modus Therapeutics Holding AB’s price range in the past 12 months?
Modus Therapeutics Holding AB lowest stock price was €0.01 and its highest was €0.33 in the past 12 months.
What is Modus Therapeutics Holding AB’s market cap?
Modus Therapeutics Holding AB’s market cap is €5.04M.
When is Modus Therapeutics Holding AB’s upcoming earnings report date?
Modus Therapeutics Holding AB’s upcoming earnings report date is May 26, 2026 which is in 4 days.
How were Modus Therapeutics Holding AB’s earnings last quarter?
Modus Therapeutics Holding AB released its earnings results on Feb 25, 2026. The company reported -€0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.004.
Is Modus Therapeutics Holding AB overvalued?
According to Wall Street analysts Modus Therapeutics Holding AB’s price is currently Overvalued.
Does Modus Therapeutics Holding AB pay dividends?
Modus Therapeutics Holding AB does not currently pay dividends.
What is Modus Therapeutics Holding AB’s EPS estimate?
Modus Therapeutics Holding AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Modus Therapeutics Holding AB have?
Modus Therapeutics Holding AB has 121,628,494 shares outstanding.
What happened to Modus Therapeutics Holding AB’s price movement after its last earnings report?
Modus Therapeutics Holding AB reported an EPS of -€0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -5.882%.
Which hedge fund is a major shareholder of Modus Therapeutics Holding AB?
Currently, no hedge funds are holding shares in DE:99Z
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Modus Therapeutics Holding AB
Modus Therapeutics Holding AB (publ), a biotechnology company, develops a treatment for sepsis and septic shock in Sweden. Its lead product is Sevuparin, a polysaccharide to treat patients with sepsis and septic shock, which is under Phase Ib clinical study. The company was founded in 2011 and is headquartered in Stockholm, Sweden.
Technical Analysis
Isofol Medical AB
―
Xintela AB
―
Elicera Therapeutics AB
―
Active Biotech AB
―
NextCell Pharma AB
―